New York State Common Retirement Fund Has $56.65 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

New York State Common Retirement Fund lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 35.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 456,559 shares of the medical device company’s stock after purchasing an additional 120,236 shares during the quarter. New York State Common Retirement Fund owned 0.12% of DexCom worth $56,654,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Valley National Advisers Inc. grew its holdings in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares during the last quarter. MV Capital Management Inc. lifted its position in shares of DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares during the period. Washington Trust Advisors Inc. lifted its position in shares of DexCom by 120.6% in the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after purchasing an additional 193 shares during the period. Turtle Creek Wealth Advisors LLC acquired a new position in shares of DexCom in the 4th quarter worth approximately $57,000. Finally, NBC Securities Inc. acquired a new position in shares of DexCom in the 3rd quarter worth approximately $47,000. 97.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DXCM. Raymond James boosted their price target on shares of DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 23rd. Royal Bank of Canada initiated coverage on shares of DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. UBS Group boosted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Citigroup boosted their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $141.40.

DexCom Price Performance

DXCM opened at $134.00 on Wednesday. The firm has a market cap of $51.66 billion, a P/E ratio of 102.29, a PEG ratio of 2.26 and a beta of 1.20. The firm has a 50-day moving average of $130.15 and a 200 day moving average of $117.74. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.07. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The firm’s revenue for the quarter was up 26.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.34 earnings per share. On average, research analysts expect that DexCom, Inc. will post 1.76 EPS for the current year.

Insider Buying and Selling at DexCom

In other news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the sale, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the sale, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Jereme M. Sylvain sold 3,363 shares of the stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the sale, the chief financial officer now directly owns 71,142 shares in the company, valued at $8,304,405.66. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock valued at $25,530,859 over the last three months. 0.41% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.